Loading clinical trials...
Loading clinical trials...
An Adaptive, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
Conditions
Interventions
RL-007 (Inidascamine)
Placebo
Locations
36
United States
Recognify Research Site
Culver City, California, United States
Collaborative Neuroscience Research
Garden Grove, California, United States
Recognify Research Site
Lafayette, California, United States
Recognify Research Site
Oceanside, California, United States
Recognify Research Site
Orange, California, United States
Recognify Research Site
Torrance, California, United States
Start Date
December 8, 2022
Primary Completion Date
April 9, 2025
Completion Date
April 9, 2025
Last Updated
July 30, 2025
NCT06894212
NCT06223672
NCT07101380
NCT04226898
NCT06121544
NCT07504276
Lead Sponsor
Recognify Life Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions